CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
February 21 2008 - 4:01PM
PR Newswire (US)
PALO ALTO, Calif., Feb. 21 /PRNewswire-FirstCall/ -- CV
Therapeutics, Inc. (NASDAQ:CVTX) announced today that 11 abstracts
on clinical and preclinical studies have been accepted for
presentation at the American College of Cardiology (ACC) 57th
Annual Scientific Session, which will be held in Chicago, IL on
March 29 - April 1, 2008. Ranexa(R) (ranolazine extended-release
tablets): Ranolazine Suppresses Ectopic Activity in Isolated Rat
Left Atrial Appendage; Poster; Sunday, March 30, 2008, 10:00 a.m.
CST Ranolazine Attenuates Palmitoyl-L-Carnitine Induced Ventricular
Diastolic Dysfunction; Poster; Sunday, March 30, 2008, 11:00 a.m.
CST Ranolazine's Mechanism of Action for Reducing Myocardial
Infarct Size is Independent of Changes in Coronary Collateral Blood
Flow; Poster, Sunday, March 30, 2008, 11:00 a.m. CST Ranolazine
Prevents Ischemia-Induced ST Segment Changes and Left Ventricular
Mechanical Dysfunction in Rabbits; Poster, Sunday, March 30, 2008,
11:00 a.m. CST Ranolazine Increases Glucose Stimulated Insulin
Secretion in Rats; Poster, Monday, March 31, 2008, 10:00 a.m. CST
Ranolazine Shortens Repolarization and Improves Myocardial
Relaxation in Patients with Type-3 Long QT Syndrome; Poster,
Monday, March 31, 2008, 10:00 a.m. CST Chronic Kidney Disease,
Cardiovascular Outcomes, and Treatment Disparities Following Non-ST
Elevation Myocardial Infarction; Poster, Monday, March 31, 2008,
3:00 p.m. CST Effects of Ranolazine on Disease-Specific Health
Status and Quality of Life: Results from the MERLIN-TIMI 36
Randomized Trial; Poster, Monday, March 31, 2008, 3:00 p.m. CST
Myeloperoxidase Levels Associated with Risk of Cardiovascular Death
and Heart Failure after Non-ST Elevation Acute Coronary Syndrome;
Poster, Monday, March 31, 2008, 3:00 p.m. CST Efficacy and Safety
of Ranolazine in Chronic Angina: Observations from the Randomized,
Double-blind, Placebo-controlled MERLIN-TIMI 36 Trial; Poster,
Tuesday, April 1, 2008, 11:00 a.m. CST Regadenoson Heart Rate
Response to Adenosine and Regadenoson in Diabetes Mellitus: A
Marker of Autonomic Cardiac Neuropathy; Poster, Tuesday, April 1,
2008, 11:30 a.m. CST Additional information regarding the ACC 57th
Annual Scientific Sessions can be accessed at
http://acc08.acc.org/Pages/default.aspx. About CV Therapeutics CV
Therapeutics, Inc., headquartered in Palo Alto, California, is a
biopharmaceutical company primarily focused on applying molecular
cardiology to the discovery, development and commercialization of
novel, small molecule drugs for the treatment of cardiovascular
diseases. CV Therapeutics' approved product, Ranexa(R) (ranolazine
extended-release tablets), is indicated for the treatment of
chronic angina in patients who have not achieved an adequate
response with other antianginal drugs, and should be used in
combination with amlodipine, beta-blockers or nitrates. CV
Therapeutics' clinical and preclinical drug development candidates
and programs include regadenoson, which is being developed for
potential use as a pharmacologic stress agent in myocardial
perfusion imaging studies, and CVT- 6883, which is being developed
for potential treatment of cardiopulmonary diseases. Regadenoson
and CVT-6883 have not been determined by any regulatory authorities
to be safe or effective in humans for any use. Except for the
historical information contained herein, the matters set forth in
this press release are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially, including operating losses and fluctuations in
operating results; capital requirements; regulatory review and
approval of our products; special protocol assessment agreement;
the conduct and timing of clinical trials; commercialization of
products; market acceptance of products; product labeling; and
other risks detailed from time to time in CV Therapeutics' SEC
reports, including its Quarterly Report on Form 10-Q for the
quarter ended September 30, 2007. CV Therapeutics disclaims any
intent or obligation to update these forward- looking statements.
DATASOURCE: CV Therapeutics, Inc. CONTACT: Investor and Media
Contact: John Bluth, Executive Director, Corporate Communications
& Investor Relations of CV Therapeutics, Inc., +1-650-384-8850
Web site: http://www.cvt.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Jul 2023 to Jul 2024